[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583383":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":30,"centralContacts":35,"locations":41,"responsibleParty":60,"collaborators":62,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":10,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":10,"enrollmentInfo":77,"targetDuration":10,"studyType":80,"phases":10,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Massachusetts Eye and Ear Infirmary","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Post-Operative Cohort",null,"Cutaneous Squamous Cell Carcinoma cancer patients treated with surgery.",[13],"Diagnostic Test: Blood and Tissue Collection",{"label":15,"type":10,"description":16,"interventionNames":17},"Neoadjuvant Cohort","Cutaneous Squamous Cell Carcinoma patients treated with Neoadjuvant immunotherapy.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Definitive Immunotherapy Cohort","Cutaneous Squamous Cell Carcinoma patients treated with definitive immunotherapy.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DIAGNOSTIC_TEST","Blood and Tissue Collection","Blood samples, and tissue samples will be collected from the participants, and used to determine whether circulating tumor DNA (ctDNA) testing can help monitor treatment in patients with CSCC, and to determine how ctDNA levels change in patients.",[19,15,9],[29],"ctDNA test",[31],{"name":32,"affiliation":33,"role":34},"Sophia Z. Shalhout, PhD","Massachusetts Eye and Ear","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},"Michael Cheung, MSc, CCRP","CONTACT","6175736060","mcheung0@meei.harvard.edu",[42],{"facility":33,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-71.05977,42.35843,{"lat":53,"lon":52},[56,58],{"name":37,"role":38,"phone":57,"phoneExt":10,"email":40},"617-573-6060",{"name":59,"role":34,"phone":10,"phoneExt":10,"email":10},"Sophia Shalhout, PhD",{"type":34,"investigatorFullName":59,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Assistant Professor",[63,66],{"name":64,"class":65},"Haystack Oncology, Inc.","UNKNOWN",{"name":67,"class":6},"Massachusetts General Hospital","100583383","ctdna-in-cutaneous-squamous-cell-carcinoma-100583383",false,"NCT06875609","ctDNA in Cutaneous Squamous Cell Carcinoma","ctDNA Clearance and ctDNA Monitoring Study in Cutaneous Squamous Cell Carcinoma","Post-Operative Cohort\n\nInclusion Criteria:\n\n* Patients with surgically resectable primary CSCC with PNI (\\>0.1mm caliber nerve) or at least 2 high-risk features defined as size \\> 2cm, recurrent CSCC, LVI, immunosuppressed, poorly differentiated, and\u002For invasion \\>6mm\u002Fbeyond subcutaneous fat;\n* Patients with surgically resectable regional metastases not receiving neoadjuvant therapy\n\nExclusion Criteria:\n\n* Patients with Cutaneous Squamous Cell Carcinoma not amenable to surgical resection\n* Patients receiving or undergoing systemic therapies.\n\nNeoadjuvant Cohort\n\nInclusion Criteria:\n\n* Patients with resectable AJCC (8th ed) Stage II, III or IV(M0) CSCC treated with neoadjuvant immunotherapy as part of standard care.\n\nExclusion Criteria:\n\n* Patients ineligible for neoadjuvant treatment.\n\nDefinitive Immunotherapy Cohort\n\nInclusion Criteria:\n\n* Patients with unresectable locally advanced or metastatic CSCC, AJCC (8th ed) Stage II, III, or IV), receiving immunotherapy as part of standard of care.\n\nExclusion Criteria:\n\n* Patients undergoing systemic therapies outside the standard of care or enrolled in conflicting clinical trials.","ALL","18 Years",{"count":78,"type":79},60,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to test the potential for a liquid biopsy assay to detect residual disease after surgery in patients with cutaneous squamous cell carcinoma as well as the potential for this assay to monitor response to immunotherapy treatment.",[83],"Cutaneous Squamous Cell Carcinoma",[85,86,87,88,89,90,91,92],"Circulating Tumor DNA","CSCC","Skin cancer","Biomarker","ctDNA","Minimal Residual Disease (MRD)","Liquid Biopsy","Advanced Skin Cancer","2026-03-26",{"date":95,"type":96},"2026-03-30","ACTUAL",{"date":98,"type":96},"2025-03-24",{"date":100,"type":79},"2029-04-30",{"name":5,"class":6},1]